Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy

References

• Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811; PMID:10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, Aridome K, Hokita S, Aikou T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103-8; PMID:10974412; http://dx.doi.org/10.1016/S0304-3835(00)00542-5
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S, Takao S, Aikou T. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237-40; PMID:12883687; http://dx.doi.org/10.3892/or.10.5.1237
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M, Tanigawa N. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92-7; PMID:12532424; http://dx.doi.org/10.1002/ijc.10915
   PubMed Web of Science ®Google Scholar
• Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920-31; PMID:18836473; http://dx.doi.org/10.1038/onc.2008.270
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic Cell Death in Cancer Therapy. Ann Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451-3; PMID:23243626; http://dx.doi.org/10.4161/onci.21356
   PubMed Web of Science ®Google Scholar
• Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S et al. Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468
   PubMed Web of Science ®Google Scholar
• Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199:251-63; PMID:15233739; http://dx.doi.org/10.1111/j.0105-2896.2004.00139.x
   PubMed Web of Science ®Google Scholar
• Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164:5508-14; PMID:10799919; http://dx.doi.org/10.4049/jimmunol.164.10.5508
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63:2127-33; PMID:12727829
   PubMed Web of Science ®Google Scholar
• Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HG, Pascolo S. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61:2418-24; PMID:15378210; http://dx.doi.org/10.1007/s00018-004-4255-0
   PubMed Web of Science ®Google Scholar
• Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30:1-7; PMID:10602021; http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-
   PubMed Web of Science ®Google Scholar
• Heine A, Holderried TAW, Brossart P. Immunotherapy in renal cell carcinoma. Immunotherapy 2009; 1:97-107; PMID:20635977; http://dx.doi.org/10.2217/1750743X.1.1.97
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. A novel, disruptive vaccination technology: self-adjuvantedRNActive((R)) vaccines. Hum VaccinImmunother 2013; 9:2263-76; PMID:23921513; http://dx.doi.org/10.4161/hv.25181
   PubMed Web of Science ®Google Scholar
• Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WPR, Brock R, Probst J, Schlake T. Protein expression from exogenous mRNA Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 2011; 8:627-36; PMID:21654214; http://dx.doi.org/10.4161/rna.8.4.15394
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G et al. Trial Watch Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013 Oct 1; 2(10); PMID:24286020; http://dx.doi.org/10.4161/onci.25771
   Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. IMPACT Study Investigators. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23:65-71; PMID:21436185; http://dx.doi.org/10.1093/annonc/mdr034
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I et al. Intradermal Vaccinations With RNA Coding for TAA Generate CD8(+) and CD4(+) Immune Responses and Induce Clinical Benefit in Vaccinated Patients. MolTher 2011; 19:990-9; PMID:21189474; http://dx.doi.org/10.1038/mt.2010.289
   PubMedGoogle Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J ClinOncol 1999; 17:2530-40; PMID:10561319
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie WL, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. J ClinOncol 2009; 27:5794-9; PMID:19826129; http://dx.doi.org/10.1200/JCO.2008.21.4809
   PubMed Web of Science ®Google Scholar
• Pal SK, Nelson RA, Vogelzang N. Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era. PLoS One 2013; 8 (5):e63341; PMID:23658823; http://dx.doi.org/10.1371/journal.pone.0063341
   PubMed Web of Science ®Google Scholar
• Kroeger N, Xie WL, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999-3006; PMID:23696129; http://dx.doi.org/10.1002/cncr.28151
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie WL, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141-8; PMID:23312463; http://dx.doi.org/10.1016/S1470-2045(12)70559-4
   PubMed Web of Science ®Google Scholar
• Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP. Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. J OncolPract 2014; 10(2):e63-72; PMID:24281152; http://dx.doi.org/10.1200/JOP.2013.001180
   PubMedGoogle Scholar
• Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 2011; 29(3):361-6; PMID:21461939; http://dx.doi.org/10.1007/s00345-011-0673-4
   PubMed Web of Science ®Google Scholar
• Wahlgren T, Harmenberg U, Sandström P, Lundstam S, Kowalski J, Jakobsson M, Sandin R, Ljungberg B. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer 2013; 108(7):1541-9; PMID:23531701; http://dx.doi.org/10.1038/bjc.2013.119
   PubMed Web of Science ®Google Scholar
• Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN Jr. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. ClinGenitourin Cancer 2012; 10(2):93-98; PMID:22382008; http://dx.doi.org/10.1016/j.clgc.2012.01.007
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al. Nivolumabvs.Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; Nov 5; 373(19):1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665.
   Web of Science ®Google Scholar
• Wolf D, Heine A, Brossart P. Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014; 3:e27588; PMID:24800168; http://dx.doi.org/10.4161/onci.27588
   PubMedGoogle Scholar
• Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S.Gene Ther. 2007 Aug; 14(15):1175-80
   Google Scholar